Napatawn BanchuinWatip BoonyasrisawatSathit VannasaengTararaj DharakulPa Thai YenchitsomanusChaicharn DeerochanawongSirirat PloybutrSutin SriussadapornThawatchai PasurakulMahidol UniversityRajavithi HospitalPhya Thai 2 Hospital2018-07-242018-07-242002-03-04Diabetes Research and Clinical Practice. Vol.55, No.3 (2002), 237-245016882272-s2.0-0036177952https://repository.li.mahidol.ac.th/handle/20.500.14594/20076We measured the cell-mediated immune response to GAD and bovine β-casein in 38 type 1 and 37 type 2 diabetic patients who visited diabetic clinics or who were hospitalized in Bangkok, Thailand, and in 43 normal controls, by using a lymphoproliferation assay. Positive results against GAD were found in 29/38 (76.3%) type 1, 6/37 (16.2%) type 2 diabetic patients and 1/43 (2.3%) normal controls. Positive results against bovine β-casein were found in 18/38 (47.4%), 5/37 (13.5%) and 1/43 (2.3%) of these subjects, respectively. The frequencies of the positive results and the magnitude of the responses to both antigens in type 1 diabetic patients were significantly higher than those in the other two groups (P<0.001). In addition, the prevalence of a positive lymphoproliferative response to these antigens in type 1 diabetic patients was higher than that of anti-GAD antibody positivity in the same group of subjects (26.3%). Thus, the prevalence of positive lymphoproliferative response to GAD in type 1 diabetic patients studied was higher than the prevalence of other autoimmune markers previously reported in type 1 diabetic patients in Thailand. Copyright © 2002 Elsevier Science Ireland Ltd.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyMedicineArticleSCOPUS10.1016/S0168-8227(01)00322-9